18 April 2023 - The FDA’s glacial pace at reviewing and approving new drugs has an enormous opportunity cost for society in terms of lives lost and illnesses prolonged.

For instance, while the FDA has received much praise for its ability to approve a vaccine for Covid within eight months of the pandemic, its inability to move with a similar urgency to approve a home flu test—ostensibly because they were not quite accurate enough—meant that no such tests were available until after vaccinations were widely available.

Read Forbes article